Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision Making
Anna Kondic, Dean Bottino, John Harrold, Jeffrey D. Kearns, CJ Musante, Aleksandrs Odinecs, Saroja Ramanujan, Jangir Selimkhanov, Birgit Schoeberl
Source record
Source: Crossref
Published: Apr 12, 2022
DOI: 10.3389/fphar.2022.860881
Open original source ↗Source abstract
The goal of this mini-review is to summarize the collective experience of the authors for how modeling and simulation approaches have been used to inform various decision points from discovery to First-In-Human clinical trials. The article is divided into a high-level overview of the types of problems that are being aided by modeling and simulation approaches, followed by detailed case studies around drug design (Nektar Therapeutics, Genentech), feasibility analysis (Novartis Pharmaceuticals), improvement of preclinical drug design (Pfizer), and preclinical to clinical extrapolation (Merck, Takeda, and Amgen).
Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.